Here are Lundbeck’s best-performing drugs
A number of drugs in Danish company Lundbeck’s portfolio are performing so well that it has led to a positive adjustment of the company’s guidance for annual turnover.
by Leonora Beck
A number of Lundbeck’s drugs are generating more profit than the Danish company expected them to. The extra money set to make it onto Lundbeck’s top line sees the Danish group raising its expectations for annual turnover to DKK 14.8-15.2bn (USD 2.7-2.75bn) from the previous guidance of DKK 14.6-15.0bn (USD 2.65-2.72bn).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Lundbeck launches alcohol pill in Denmark
For abonnenter
Lundbeck makes good money off of other drug companies
For abonnenter
Lundbeck’s alcohol pill hits speed bump
For abonnenter
.jpg&w=384&q=75)
